§ 01

Overview

N S A I Ds

N S A I Ds

Mechanism of Action Diagram

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for pain management worldwide, spanning over-the-counter agents like ibuprofen and naproxen to prescription formulations like celecoxib and indomethacin. They work by inhibiting cyclooxygenase (COX) enzymes, which reduces the synthesis of prostaglandins — key mediators of inflammation, pain sensitization, and fever.

For myofascial pain syndrome (myofascial pain) and trigger point pain, NSAIDs provide moderate benefit. They reduce inflammation and lower the pain threshold at peripheral nociceptors, which helps alleviate the soreness and tenderness associated with active trigger points. However, they do not address the fundamental pathophysiology of the trigger point itself — the dysfunctional motor endplate, sustained sarcomere contraction, local ischemia, and the self-perpetuating energy crisis that defines the myofascial trigger point.

While NSAIDs reduce inflammation effectively, myofascial trigger points involve more than inflammation — which is why NSAIDs alone rarely resolve the problem.

NSAIDs are most useful for acute flares of myofascial pain and as part of a multimodal treatment strategy. They can reduce pain enough to facilitate participation in physical therapy, stretching programs, and other active interventions that directly address the trigger point. Used alone as chronic daily therapy, they offer incomplete relief and expose the patient to cumulative gastrointestinal, cardiovascular, and renal risks without resolving the underlying cause of pain.

§ 02

Mechanism of Action

NSAIDs exert their therapeutic effects through inhibition of cyclooxygenase enzymes, blocking the conversion of arachidonic acid to prostaglandins. Understanding the distinction between COX-1 and COX-2 inhibition is essential for both therapeutic use and risk management.

Mechanism of Action

Mechanism of Action

Mechanism Diagram

COX-1 Inhibition

COX-1 is a constitutive enzyme expressed in nearly all tissues, including the gastrointestinal mucosa, kidneys, and platelets. It maintains protective prostaglandin production for gastric mucosal integrity (PGE2, PGI2), renal blood flow regulation, and platelet aggregation via thromboxane A2 (TXA2). Inhibition of COX-1 is primarily responsible for the adverse effects of NSAIDs — gastric erosion, impaired renal perfusion, and antiplatelet activity — rather than their therapeutic benefit in pain management.

COX-2 Inhibition (Primary Therapeutic Target)

COX-2 is an inducible enzyme upregulated at sites of tissue injury and inflammation. It is the primary therapeutic target of NSAIDs for pain relief. At trigger point sites, inflammatory mediators stimulate COX-2 expression, which drives the production of pronociceptive prostaglandins. By selectively blocking COX-2, NSAIDs reduce prostaglandin synthesis at the source of pain without — in theory — the same degree of GI and platelet side effects (though selectivity varies by agent).

Prostaglandin Synthesis Pathway

The pathway begins with membrane phospholipids being cleaved by phospholipase A2 to release arachidonic acid. COX enzymes then convert arachidonic acid to PGG2, which is subsequently reduced to PGH2. PGH2 is the common precursor for all prostanoids: PGE2 (pain sensitization, inflammation, fever), PGI2 / prostacyclin (vasodilation, gastric protection), and TXA2 / thromboxane (platelet aggregation, vasoconstriction). NSAIDs block the conversion of arachidonic acid to PGG2, shutting down the entire downstream cascade.

Peripheral Nociceptor Sensitization Reversal

PGE2 is the key prostaglandin responsible for peripheral pain sensitization. It binds to EP receptors on nociceptor terminals, activating protein kinase A (PKA) and protein kinase C (PKC) signaling cascades that phosphorylate tetrodotoxin-resistant sodium channels (Nav1.8, Nav1.9) and TRPV1 receptors. This lowers the firing threshold of nociceptors, causing previously non-painful stimuli to become painful (allodynia) and painful stimuli to be amplified (hyperalgesia). NSAIDs reverse this sensitization by reducing PGE2 levels.

Central COX-2 Inhibition

COX-2 is also expressed in the spinal cord dorsal horn, where it contributes to central sensitization — a state of amplified pain processing in the central nervous system. Persistent nociceptive input from trigger points induces spinal COX-2 expression, leading to elevated PGE2 in the cerebrospinal fluid. This enhances excitatory glutamatergic transmission and reduces inhibitory glycinergic transmission in dorsal horn neurons. NSAIDs that cross the blood-brain barrier (most lipophilic NSAIDs do) can reduce this central sensitization component.

Additional Non-COX Mechanisms

Some NSAIDs exert effects beyond COX inhibition. Diclofenac and aspirin can inhibit NF-kappaB, a transcription factor that drives expression of inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Certain NSAIDs reduce substance P release from sensory nerve terminals and may modulate nitric oxide production. These pleiotropic effects contribute variably to the overall analgesic profile but are not the primary mechanism of action for most NSAIDs in clinical use.
§ 03

Non-Selective COX Inhibitors

Non-selective NSAIDs inhibit both COX-1 and COX-2. They are the most widely available and commonly used class, with several members available over the counter. Their lack of COX selectivity means they provide effective anti-inflammatory and analgesic effects but carry a higher risk of GI side effects compared to COX-2 selective agents.

Ibuprofen

Non-Selective

Advil, Motrin

Dosing200–800 mg every 6–8 hours
Max Daily Dose3,200 mg/day
Half-Life2 hours
The most commonly used NSAID worldwide. Available OTC (200–400 mg) and Rx (600–800 mg). Short half-life requires frequent dosing for sustained relief. Rapid onset (30–60 minutes). Generally preferred as first-line oral NSAID for acute trigger point pain due to extensive safety data and wide availability.
Best For →Best For — Acute Myofascial Pain Syndrome flares

Naproxen

Non-Selective

Aleve, Naprosyn

Dosing250–500 mg every 12 hours
Max Daily Dose1,250 mg/day (first day may be 1,500 mg)
Half-Life12–17 hours
The long half-life allows convenient twice-daily dosing, which improves adherence. Naproxen is generally considered to have the most favorable cardiovascular safety profile among all NSAIDs, making it the preferred choice for patients with cardiovascular risk factors. Slightly higher GI risk compared to ibuprofen due to longer duration of COX-1 suppression.
Best For →Best For — Sustained relief with once or twice daily dosing. Considered the safest NSAID for cardiovascular risk.

Diclofenac

Non-Selective

Voltaren, Cataflam

Dosing50–75 mg every 8–12 hours (oral)
Max Daily Dose150 mg/day
Half-Life1.2–2 hours
Available in oral, topical gel (1%), topical patch, and suppository formulations. The topical form is especially valuable for myofascial pain because it delivers therapeutic concentrations directly to superficial musculoskeletal tissues while minimizing systemic exposure. Oral diclofenac has a somewhat higher hepatic and cardiovascular risk compared to ibuprofen and naproxen.
Best For →Best For — Localized myofascial pain

Piroxicam

Non-Selective

Feldene

Dosing20 mg once daily
Max Daily Dose20 mg/day
Half-Life50 hours
Rarely used as first-line for myofascial pain due to its very long half-life and correspondingly higher GI risk. The prolonged COX-1 suppression increases the likelihood of peptic ulceration, especially in elderly patients. May be considered when once-daily dosing is essential and shorter-acting agents have failed.
Best For →Best For — Once-daily dosing for chronic use. Very long half-life provides steady-state coverage.

Indomethacin

Non-Selective

Indocin

Dosing25–50 mg every 8 hours
Max Daily Dose200 mg/day
Half-Life4.5 hours
A very potent COX inhibitor with significant central nervous system penetration. Known for more frequent CNS side effects (headache, dizziness, confusion) compared to other NSAIDs. Reserved for cases where other NSAIDs have failed. Higher GI toxicity. Not a first-line choice for typical trigger point pain.
Best For →Best For — Refractory cases

Ketoprofen

Non-Selective

Orudis, Oruvail

Dosing50–75 mg every 6–8 hours
Max Daily Dose300 mg/day
Half-Life2–4 hours
While the oral form is available in the US, the topical gel formulation (available in Europe and other markets) has demonstrated excellent tissue penetration for musculoskeletal pain. Some studies suggest superior skin permeation compared to topical diclofenac. Oral ketoprofen has a similar efficacy and side effect profile to ibuprofen.
Best For →Best For — Available as topical gel in many countries outside the US. Good tissue penetration when applied topically.
§ 04

COX-2 Selective Inhibitors (Coxibs)

Coxibs were developed to provide the anti-inflammatory and analgesic benefits of NSAIDs while sparing COX-1, thereby reducing GI toxicity. While they achieve this goal, concerns about cardiovascular safety emerged after rofecoxib (Vioxx) was withdrawn from the market in 2004 due to increased risk of myocardial infarction.

Celecoxib

COX-2 Selective

Celebrex

Dosing100–200 mg every 12 hours
Max Daily Dose400 mg/day
Half-Life11 hours
The only COX-2 selective inhibitor remaining on the US market after the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra). Provides anti-inflammatory and analgesic efficacy comparable to non-selective NSAIDs with a substantially lower risk of serious GI events. Cardiovascular risk is dose-dependent — the 200 mg twice daily dose carries higher CV risk than lower doses. The PRECISION trial showed non-inferiority to naproxen and ibuprofen for CV safety at moderate doses (100–200 mg BID).
Best For →Best For — Patients at higher GI risk who need an oral NSAID

Etoricoxib

COX-2 Selective

Arcoxia

Dosing60–90 mg once daily
Max Daily Dose120 mg/day
Half-Life22 hours
Not available in the United States (the FDA did not approve it), but widely used in Europe, Asia, Latin America, and other markets. Has the highest COX-2 selectivity among available coxibs. The long half-life allows convenient once-daily dosing. Provides effective analgesia for musculoskeletal pain. Cardiovascular profile similar to other coxibs — dose-dependent risk increase.
Best For →Best For — Once-daily dosing with strong COX-2 selectivity
§ 05

Topical NSAIDs (Often Best for myofascial pain)

Topical NSAIDs deserve special emphasis for myofascial pain syndrome because they deliver drug directly to the affected musculoskeletal tissue with minimal systemic absorption. For superficial trigger points — which account for a large proportion of clinically relevant trigger points — topical NSAIDs can achieve tissue concentrations comparable to oral dosing while exposing the patient to a fraction of the systemic risk.

Diclofenac 1% Gel (Voltaren Gel)

Apply 4 g to affected area 4 times daily

Bioavailability:6–17% of oral bioavailability
The gold standard for topical NSAID treatment of localized musculoskeletal pain. Delivers therapeutic drug concentrations to underlying muscle tissue while achieving plasma levels that are a small fraction of those from equivalent oral doses. This substantially reduces GI, CV, and renal risk. Available OTC in many countries. The gel penetrates through skin into subcutaneous tissue and superficial muscles. Multiple RCTs demonstrate efficacy for localized musculoskeletal pain.
Best For →Superficial trigger points accessible by topical application — upper trapezius, rhomboids, forearm extensors, tibialis anterior

Diclofenac Patch (Flector Patch)

Apply 1 patch to affected area every 12 hours

Bioavailability:Very low systemic absorption
Contains 180 mg diclofenac epolamine per patch (13 cm x 10 cm). Provides sustained local drug delivery over 12 hours. The patch format ensures consistent dosing and can be applied directly over the trigger point area. Systemic absorption is minimal. Particularly useful for workplace or athletic settings where repeated gel application is impractical.
Best For →Targeted delivery to a specific trigger point region

Ketoprofen Gel (2.5%)

Apply 2–4 g to affected area 2–3 times daily

Bioavailability:Low systemic absorption
Not available in the United States but widely used internationally. Ketoprofen has favorable lipophilic properties that promote skin permeation and tissue penetration. Some comparative studies suggest it achieves higher concentrations in deep musculoskeletal tissues than topical diclofenac. The 2.5% concentration is the most commonly prescribed formulation in Europe.
Best For →Available in Europe and many other markets
§ 06

Clinical Evidence for myofascial pain

Moderate EvidenceSymptomatic relief, not definitive treatment

The evidence for NSAIDs in myofascial pain syndrome is best characterized as moderate. While multiple studies demonstrate statistically significant pain reduction compared to placebo, the magnitude of benefit is modest — a meaningful but limited improvement in pain intensity on visual analogue scales for many patients. NSAIDs consistently outperform placebo for acute musculoskeletal pain but show diminishing returns with chronic use.

The strongest evidence supports the use of topical diclofenac for localized musculoskeletal pain, with multiple high-quality RCTs demonstrating efficacy with minimal systemic side effects. For oral NSAIDs, the evidence base primarily supports short-term use (less than two weeks) for acute flares rather than long-term maintenance therapy.

The work of Shah and colleagues, who measured the biochemical milieu at active trigger points, provides a compelling rationale for anti-inflammatory treatment: active trigger points have elevated levels of inflammatory mediators including prostaglandins, bradykinin, substance P, CGRP, TNF-alpha, and interleukins. These findings support the biological plausibility of NSAIDs for trigger point pain but also highlight that inflammation is only one component of the trigger point pathophysiology.

Modest Pain Reduction

Meaningful but limited improvement on VAS in clinical studies

Best for Acute Flares

Short courses more effective than chronic daily use

Topical Diclofenac

Strongest evidence for localized musculoskeletal pain
§ 07

GI, Cardiovascular & Renal Risks

§ 08

Practical Prescribing for myofascial pain

First-Line: Topical Diclofenac for Localized Trigger Points

For most patients with localized trigger point pain in accessible muscles (upper trapezius, cervical paraspinals, forearm extensors, tibialis anterior), topical diclofenac 1% gel applied 4 times daily or diclofenac patches applied every 12 hours directly over the trigger point area should be the first pharmacological intervention. This provides local anti-inflammatory and analgesic benefit with minimal systemic risk.

Oral NSAIDs: Short Courses for Acute Flares

When oral NSAIDs are needed, prescribe short courses of 5 to 10 days for acute flares. Ibuprofen 400 to 600 mg three times daily or naproxen 250 to 500 mg twice daily are reasonable first-line oral options. The goal is to reduce pain enough to participate in active rehabilitation (physical therapy, stretching, trigger point interventions) rather than long-term pain suppression.

Avoid Chronic Daily Use

Chronic daily oral NSAID use for myofascial pain is a clinical red flag that the underlying trigger points are not being adequately treated. Rather than escalating to higher doses or longer courses, address the root cause with definitive trigger point treatment — dry needling, trigger point injections, manual therapy, and correction of perpetuating factors (ergonomics, postural dysfunction, sleep, nutritional deficiencies).

GI Protection When Indicated

Co-prescribe a proton pump inhibitor (e.g., omeprazole 20 mg daily) when risk factors are present: age over 65, prior ulcer or GI bleed, concurrent corticosteroids or anticoagulants, or when oral NSAID use will exceed 10 days. Consider celecoxib as an alternative with inherently lower GI risk in patients who require ongoing oral NSAID therapy.

Cardiovascular Risk: Prefer Naproxen

For patients with cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking, family history of CVD), naproxen is the preferred oral NSAID due to its more favorable CV safety profile. Avoid all oral NSAIDs in patients with established cardiovascular disease unless the clinical benefit clearly outweighs the risk and no alternatives are available.

Absolute Contraindications

Avoid oral NSAIDs in patients with: chronic kidney disease (GFR below 30 mL/min), active GI bleeding or untreated peptic ulcer disease, third-trimester pregnancy (risk of premature ductus arteriosus closure), known NSAID hypersensitivity or aspirin-exacerbated respiratory disease, and patients immediately post-CABG surgery.
§ 09

NSAIDs vs Other Pain Medications for myofascial pain

NSAIDs vs Other Pain Medications for myofascial pain

NSAIDs vs Other Pain Medications for myofascial pain

Comparison Chart
Feature
NSAIDsAcetaminophenMuscle RelaxantsTopical LidocaineOpioids

Mechanism

COX inhibition, reduces prostaglandin synthesis
Central COX inhibition, weak peripheral action. No anti-inflammatory effect.
CNS depression (cyclobenzaprine), alpha-2 agonism (tizanidine)
Sodium channel blockade, local nerve conduction inhibition
Mu-opioid receptor agonism, central pain pathway modulation

Anti-inflammatory

Yes — primary mechanism
No (or negligible)
No
No
No

Pain Reduction for myofascial pain

Moderate
Mild
Moderate (muscle spasm component)
Moderate (localized)
Strong but inappropriate for chronic myofascial pain

Addresses Trigger Point

No — symptom management only
No
Partially — reduces taut band tension
Partially — blocks local nociception
No — masks pain, no structural benefit

GI Risk

Moderate to high (chronic use)
Low
Low
None
Low (constipation common)

CV Risk

Dose- and duration-dependent
Low
Low
None
Low

Dependence / Abuse

None
None
Low (sedation tolerance)
None
High — not recommended for myofascial pain

Best Use in myofascial pain

Acute flares, multimodal regimen adjunct
Mild pain, NSAID contraindicated
Sleep disruption, acute spasm
Localized trigger point pain
Avoid — rarely if ever appropriate

OTC Available

Yes (ibuprofen, naproxen, topical diclofenac)
Yes
No (prescription only)
Yes (4% patches/creams)
No
Key Takeaways

  1. NSAIDs provide MODERATE benefit for myofascial trigger point pain — they reduce inflammation and pain sensitization but do not resolve the underlying trigger point contracture, motor endplate dysfunction, or local ischemia.

  2. Topical NSAIDs (diclofenac gel, diclofenac patch) should be considered FIRST-LINE for localized trigger point pain because they deliver drug directly to the affected tissue with minimal systemic exposure and dramatically lower GI, CV, and renal risk.

  3. Oral NSAIDs are best used in SHORT COURSES (5–10 days) for acute myofascial pain flares, not as chronic daily therapy. The goal is to reduce pain enough to participate in active rehabilitation — physical therapy, stretching, and trigger point interventions.

  4. Naproxen has the most favorable cardiovascular safety profile among oral NSAIDs and should be preferred in patients with any CV risk factors. Celecoxib offers a better GI profile at the cost of requiring a prescription.

  5. NEVER use NSAIDs as a standalone treatment for myofascial pain. They are most effective as part of a MULTIMODAL approach that includes physical therapy, trigger point dry needling or injections, ergonomic correction, and addressing perpetuating factors.

  6. GI protection with a PPI (proton pump inhibitor) should be co-prescribed for patients at risk: age over 65, history of peptic ulcer disease, concurrent corticosteroid or anticoagulant use, or any patient requiring more than 10 days of oral NSAID therapy.

  7. The "triple whammy" of NSAIDs combined with ACE inhibitors/ARBs and diuretics significantly increases acute kidney injury risk. Always review the full medication list before prescribing oral NSAIDs.

  8. Chronic daily NSAID use for myofascial pain is a red flag — it suggests the underlying trigger points are not being adequately treated. Reassess and pursue definitive trigger point treatment (needling, injections, manual therapy) rather than indefinite pharmacological suppression.